Literature DB >> 26884547

Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.

Arianna Marconi1, Marta Di Forti1, Cathryn M Lewis2, Robin M Murray1, Evangelos Vassos3.   

Abstract

Cannabis use has been reported to induce long-lasting psychotic disorders and a dose-response relationship has been observed. We performed a systematic review of studies that investigate the association between the degree of cannabis consumption and psychosis and a meta-analysis to quantify the magnitude of effect. Published studies were identified through search of electronic databases, supplemented by manual searches of bibliographies. Studies were considered if they provided data on cannabis consumption prior to the onset of psychosis using a dose criterion (frequency/amount used) and reported psychosis-related outcomes. We performed random effects meta-analysis of individual data points generated with a simulation method from the summary data of the original studies. From 571 references, 18 studies fulfilled inclusion criteria for the systematic review and 10 were inserted in the meta-analysis, enrolling a total of 66 816 individuals. Higher levels of cannabis use were associated with increased risk for psychosis in all the included studies. A logistic regression model gave an OR of 3.90 (95% CI 2.84 to 5.34) for the risk of schizophrenia and other psychosis-related outcomes among the heaviest cannabis users compared to the nonusers. Current evidence shows that high levels of cannabis use increase the risk of psychotic outcomes and confirms a dose-response relationship between the level of use and the risk for psychosis. Although a causal link cannot be unequivocally established, there is sufficient evidence to justify harm reduction prevention programs.
© The Author 2016. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  dose response; drug use; psychotic disorders; schizophrenia; systematic review

Mesh:

Year:  2016        PMID: 26884547      PMCID: PMC4988731          DOI: 10.1093/schbul/sbw003

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  36 in total

1.  The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being.

Authors:  L Degenhardt; W Hall
Journal:  Psychol Med       Date:  2001-05       Impact factor: 7.723

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

3.  Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors:  Louise Arseneault; Mary Cannon; Richie Poulton; Robin Murray; Avshalom Caspi; Terrie E Moffitt
Journal:  BMJ       Date:  2002-11-23

4.  Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.

Authors:  Daniel J Foti; Roman Kotov; Lin T Guey; Evelyn J Bromet
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

5.  Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults.

Authors:  John McGrath; Joy Welham; James Scott; Daniel Varghese; Louisa Degenhardt; Mohammad Reza Hayatbakhsh; Rosa Alati; Gail M Williams; William Bor; Jake M Najman
Journal:  Arch Gen Psychiatry       Date:  2010-03-01

6.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 7.  Cannabis use and earlier onset of psychosis: a systematic meta-analysis.

Authors:  Matthew Large; Swapnil Sharma; Michael T Compton; Tim Slade; Olav Nielssen
Journal:  Arch Gen Psychiatry       Date:  2011-02-07

Review 8.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

Review 9.  A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder.

Authors:  J van Os; R J Linscott; I Myin-Germeys; P Delespaul; L Krabbendam
Journal:  Psychol Med       Date:  2008-07-08       Impact factor: 7.723

10.  Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

Authors:  Marta Di Forti; Hannah Sallis; Fabio Allegri; Antonella Trotta; Laura Ferraro; Simona A Stilo; Arianna Marconi; Caterina La Cascia; Tiago Reis Marques; Carmine Pariante; Paola Dazzan; Valeria Mondelli; Alessandra Paparelli; Anna Kolliakou; Diana Prata; Fiona Gaughran; Anthony S David; Craig Morgan; Daniel Stahl; Mizanur Khondoker; James H MacCabe; Robin M Murray
Journal:  Schizophr Bull       Date:  2013-12-17       Impact factor: 9.306

View more
  164 in total

1.  Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015.

Authors:  Bridget Maloney-Hall; Sarah C Wallingford; Sarah Konefal; Matthew M Young
Journal:  Health Promot Chronic Dis Prev Can       Date:  2020-06       Impact factor: 3.240

2.  Altered brain cannabinoid 1 receptor mRNA expression across postnatal development in the MAM model of schizophrenia.

Authors:  Felipe V Gomes; Jessica R Edelson; David W Volk; Anthony A Grace
Journal:  Schizophr Res       Date:  2018-04-26       Impact factor: 4.939

3.  Persistent cannabis use among young adults with early psychosis receiving coordinated specialty care in the United States.

Authors:  Leslie Marino; Jennifer Scodes; Talia Richkin; Jean-Marie Alves-Bradford; Ilana Nossel; Melanie Wall; Lisa Dixon
Journal:  Schizophr Res       Date:  2020-05-28       Impact factor: 4.939

4.  Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?

Authors:  Jasmina Mallet; Nicolas Ramoz; Yann Le Strat; Philip Gorwood; Caroline Dubertret
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-11       Impact factor: 5.270

Review 5.  Nutraceuticals and Behavioral Therapy for Headache.

Authors:  Rebecca Barmherzig; Thilinie Rajapakse
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-10       Impact factor: 5.081

Review 6.  Cannabinoids in chronic non-cancer pain medicine: moving from the bench to the bedside.

Authors:  H Meng; A Deshpande
Journal:  BJA Educ       Date:  2020-07-21

7.  Risks and Benefits of Marijuana Use: A National Survey of U.S. Adults.

Authors:  Salomeh Keyhani; Stacey Steigerwald; Julie Ishida; Marzieh Vali; Magdalena Cerdá; Deborah Hasin; Camille Dollinger; Sodahm R Yoo; Beth E Cohen
Journal:  Ann Intern Med       Date:  2018-07-24       Impact factor: 25.391

8.  Associations between Psychiatric Disorders and Cannabis-Related Disorders Documented in Electronic Health Records.

Authors:  Anne Campbell; Steffani R Bailey; Kim A Hoffman; Javier Ponce-Terashima; Katie Fankhauser; Miguel Marino; Dennis McCarty
Journal:  J Psychoactive Drugs       Date:  2020-04-15

9.  Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.

Authors:  Kenneth S Kendler; Henrik Ohlsson; Jan Sundquist; Kristina Sundquist
Journal:  Am J Psychiatry       Date:  2019-05-06       Impact factor: 18.112

10.  Impact of first episode psychosis treatment on heavy cannabis use: Secondary analysis on RAISE-ETP study.

Authors:  Karl C Alcover; Oladunni Oluwoye; Liat Kriegel; Sterling McPherson; Michael G McDonell
Journal:  Schizophr Res       Date:  2019-08-02       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.